N
Nicole S. Spoelstra
Researcher at Anschutz Medical Campus
Publications - 50
Citations - 3079
Nicole S. Spoelstra is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 40 publications receiving 2675 citations. Previous affiliations of Nicole S. Spoelstra include University of Colorado Denver & Colorado State University.
Papers
More filters
Journal ArticleDOI
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Dawn R. Cochrane,Sebastian Bernales,Britta M. Jacobsen,Diana M. Cittelly,Erin N. Howe,Nicholas C. D'Amato,Nicole S. Spoelstra,Susan M. Edgerton,Annie Jean,Javier Sanchez Guerrero,Francisco Gómez,Satyanarayana Medicherla,Iván E. Alfaro,Emma McCullagh,Paul Jedlicka,Kathleen C. Torkko,Ann D. Thor,Anthony D. Elias,Andrew Asher Protter,Jennifer K. Richer +19 more
TL;DR: This preclinical study supports the initiation of clinical studies evaluating enzalutamide for treatment of AR+ tumors regardless of ER status, since it blocks both androgen- and estrogen- mediated tumor growth.
Journal ArticleDOI
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
TL;DR: It is found that miR-200c levels are high in well-differentiated endometrial, breast, and ovarian cancer cell lines, but extremely low in poorly differentiated cancer cells, and it is proposed that it warrants further investigation as a therapeutic strategy for aggressive, drug-resistant cancers.
Journal ArticleDOI
A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
Nicholas C. D'Amato,Thomas J. Rogers,Michael A. Gordon,Lisa I. Greene,Dawn R. Cochrane,Nicole S. Spoelstra,Travis Nemkov,Angelo D'Alessandro,Kirk C. Hansen,Jennifer K. Richer +9 more
TL;DR: An NF-κB-regulated signaling axis that promotes anoikis resistance is defined, functional connections with inflammatory modulation by the kynurenine pathway are suggested, and TDO2 is highlighted as an attractive target for treatment of this aggressive breast cancer subtype.
Journal ArticleDOI
Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
Valerie N. Barton,Nicholas C. D'Amato,Michael A. Gordon,Hanne T. Lind,Nicole S. Spoelstra,Beatrice Babbs,Richard Heinz,Anthony D. Elias,Paul Jedlicka,Britta M. Jacobsen,Jennifer K. Richer +10 more
TL;DR: It is indicated that non-LAR subtypes of TNBC are AR dependent and, moreover, that enzalutamide is a promising targeted therapy for multiple molecular sub types of AR+ TNBC.
Journal ArticleDOI
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Diana M. Cittelly,Partha Das,Nicole S. Spoelstra,Susan M. Edgerton,Jennifer K. Richer,Ann D. Thor,Frank E. Jones +6 more
TL;DR: It is suggested that miR-342 regulates tamoxifen response in breast tumor cell lines and clinical data indicates a trend towards reduced miR -342 expression and tamoxIFen resistance.